Thalidomide, a current teratogen in South America

Thalidomide, a current teratogen in South America

Author Castilla, E. E. Google Scholar
AshtonProlla, P. Google Scholar
BarredaMejia, E. Google Scholar
Brunoni, D. Google Scholar
Cavalcanti, D. P. Google Scholar
CorreaNeto, J. Google Scholar
Delgadillo, J. L. Google Scholar
Dutra, M. G. Google Scholar
Felix, T. Google Scholar
Giraldo, A. Google Scholar
Juarez, N. Google Scholar
LopezCamelo, J. S. Google Scholar
Nazer, J. Google Scholar
Orioli, I. M. Google Scholar
Paz, J. E. Google Scholar
Pessoto, M. A. Google Scholar
PinaNeto, J. M. Google Scholar
Quadrelli, R. Google Scholar
Rittler, M. Google Scholar
Rueda, S. Google Scholar
Saltos, M. Google Scholar
Sanchez, O. Google Scholar
Schuler, L. Google Scholar
Institution CEMIC
IMBICE
AACD
CLIN MONTESUR
Universidade Federal de São Paulo (UNIFESP)
CAISM
HOSP & CLIN
Universidade de São Paulo (USP)
FDN GILLOW
HOSP NINOS DR RICARDO GUTIERREZ
HOSP UNIV JJ AGUIRRE
Universidade Federal do Rio de Janeiro (UFRJ)
HOSP ITALIANO
HOSP MATERNOINFANTIL RAMON SARDA
MATERNIDAD NATALIO ARAMAYO
HOSP RODRIGUEZ ZAMBRANO
HOSP UNIV RUIZ & PAEZ
HOSP CLIN PORTO ALEGRE
Abstract Thalidomide, mainly used for the treatment of leprosy, is a current teratogen in South America, and it is reasonable to assume that at present this situation is affecting many births in underdeveloped countries. Moreover, the potential re-marketing of thalidomide for the treatment of a large variety of diseases may extend the problem to the developed world. When the drug is available, the control of its intake during early pregnancy is very difficult since most pregnancies are unintended. the ongoing occurrence of thalidomide embryopathy cases went undetected by the ECLAMC, due to several factors: (1) low populational coverage through this monitoring system; (2) pre-existence of the teratogen with its effects present in both baseline (expected) and monitored (observed) materials; and (3) lack of a defined phenotype to be monitored. Thus, if thalidomide re-enters the market throughout the world, due to the wide range of new applications, occurrence of phocomelia alone might not be sufficient to detect its effects. By a case-reference approach, the ECLAMC registered 34 thalidomide embryopathy cases born in South America after 1965 whose birthplaces correspond to endemic areas for leprosy. Phocomelia was found in five of eleven fully described cases. Thus, phocomelia alone is neither specific nor sufficient to serve as a suitable phenotype to survey the teratogenic effects of thalidomide. Therefore, a thalidomide-like phenotype, defined as any bilateral upper and/or lower limb reduction defect of the preaxial and/or phocomelia types, should be included in the routine surveillance of birth defects in all programmes. (C) 1997 Wiley-Liss, Inc.
Language English
Date 1996-12-01
Published in Teratology. New York: Wiley-liss, v. 54, n. 6, p. 273-277, 1996.
ISSN 0040-3709 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 273-277
Origin http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-9926(199612)54:6%3C273
Access rights Closed access
Type Article
Web of Science ID WOS:A1996WR64500001
URI http://repositorio.unifesp.br/handle/11600/25642

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account